与VS-101交换输血:一种旨在恢复灌注并提高携氧能力的新型聚乙二醇化血红蛋白
本研究在麻醉雄性Sprague Dawley大鼠中建立50%等容交换输血模型,比较VS-101(一种新型聚乙二醇化人血红蛋白氧载体)与乳酸林格液的效果。VS-101以1 mL/kg/min输注,维持了肌肉间质液氧分压于基线水平,平均动脉压仅短暂下降18±4 mm Hg;而乳酸林格液组间质液氧分压下降约50%,平均动脉压下降74±10 mm Hg。VS-101组全部存活至240分钟实验终点,乳酸林格液组全部在142分钟前死亡。VS-101组在210分钟内维持正常组织氧合,之后下降25%,可能源于VS-101的血管清除。作者认为需进一步阐明VS-101的有益复苏效应以支持未来临床试验。
要点
- 在50%交换输血大鼠模型中,VS-101以1 mL/kg/min输注维持了肌肉间质液氧分压于基线水平,平均动脉压仅短暂下降18±4 mm Hg(P<0.05)。
- 乳酸林格液组间质液氧分压下降约50%(P<0.05),平均动脉压下降74±10 mm Hg(P<0.05),全部动物在142分钟前死亡。
- VS-101组全部存活至240分钟实验终点,210分钟内维持正常组织氧合,之后下降25%(P<0.05 vs 基线),可能与VS-101血管清除有关。
- VS-101治疗后未观察到小动脉血管收缩效应。
- 作者认为需进一步阐明VS-101的有益复苏效应以支持未来临床试验。
适用人群与场景
- 麻醉雄性Sprague Dawley大鼠,接受50%等容交换输血(估计总血量的50%)的严重交换输血模型。
处置流程与药物剂量
- VS-101以1 mL/kg/min速度进行50%等容交换输血,观察240分钟。
- 乳酸林格液以1 mL/kg/min速度进行50%等容交换输血作为对照。
研究设计与关键结果
- 研究类型:动物实验(大鼠严重50%交换输血模型)。样本量:VS-101组n=8,乳酸林格液组n=8。
- VS-101维持间质液氧分压于基线,平均动脉压短暂下降18±4 mm Hg(P<0.05);乳酸林格液组间质液氧分压下降约50%(P<0.05),平均动脉压下降74±10 mm Hg(P<0.05)。
- VS-101组全部存活至240分钟实验终点;乳酸林格液组100%在142分钟前死亡。
- VS-101组210分钟内维持正常组织氧合,之后下降25%(P<0.05 vs 基线),可能源于VS-101血管清除。
- VS-101治疗后未观察到小动脉血管收缩。
证据类型、等级与局限
- 证据类型:动物实验(大鼠交换输血模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需进一步阐明VS-101的有益复苏效应以支持未来临床试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Blood products are the current standard for resuscitation of hemorrhagic shock. However, logistical constraints of perishable blood limit availability and prehospital use, meaning alternatives that provide blood-like responses remain an area of active investigation and development. VS-101 is a new PEGylated human hemoglobin-based oxygen carrier that avoids the logistical hurdles of traditional blood transfusion. This study sought to determine the safety and ability of VS -101 to maintain circulatory function and capillary oxygen delivery in a severe (50%) exchange transfusion (ET) model. Anesthetized, male Sprague Dawley rats were prepared for cardiovascular monitoring and phosphorescence quenching microscopy of interstitial fluid oxygen tension (P ISFo2 ) in the spinotrapezius muscle. Fifty-percent isovolemic ET of estimated total blood volume with either lactated Ringer's solution (LRS, n = 8) or VS -101 (n = 8) at 1 mL/kg/min was performed, and animals were observed for 240 min. VS -101 maintained P ISFo2 at baseline with a transient 18 ± 4 mm Hg decrease ( P < 0.05) in mean arterial pressure (MAP). In contrast, ET with LRS decreased P ISFo2 by approximately 50% ( P < 0.05) and MAP by 74 ± 10 mm Hg ( P < 0.05). All VS -101 animals survived 240 min, the experimental endpoint, while 100% of LRS animals expired by 142 min. VS -101 animals maintained normal tissue oxygenation through 210 min, decreasing by 25% ( P < 0.05 vs. baseline) thereafter, likely from VS -101 vascular clearance. No arteriolar vasoconstriction was observed following VS -101 treatment. In this model of severe ET, VS -101 effectively maintained blood pressure, perfusion, and P ISFo2 with no vasoconstrictive effects. Further elucidation of these beneficial resuscitation effects of VS -101 is warranted to support future clinical trials.
参考来源
- Nugent WH, Sheppard FR, Vandegriff KD, et al. EXCHANGE TRANSFUSION WITH VS -101: A NEW PEGYLATED-HB DESIGNED TO RESTORE PERFUSION AND INCREASE O 2 CARRYING CAPACITY. Shock. 2023. PMID: 38117095. doi:10.1097/SHK.0000000000002293
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。